WE ARE COMMITED TO

IBAB launched a joint academia-industry PhD program with Merck-Syngene on Aug 7, 2019. The first student selected under this program, Ms. Shikha Kumari, will be working in the niche area of pharmaceutical biologic development. Dr. Ralf Guenther from Merck KGaA and Dr. Saurabh A Joshi from Syngene International were present at the kick-off ceremony, and were given a tour of the IBAB campus and facilities.

Prof. MRN Murthy, who holds the AstraZeneca Chair at IBAB, received the INSA Honorary Professorship in July 2019. 

On August 6, a high level team from Yokogawa Electric Corporation, a Japanese electrical engineering and software company that specializes in measurement, control, and information technologies, visited IBAB and Bangalore Bioinnovation Centre (BBC). The Yokogawa team discussed the possibility of fostering collaborations and scientific exchange with IBAB and BBC, as they expand their operations into the Biotech and Life Sciences sectors.

Dr. Nils Lonberg and Dr. Nila Patil visited IBAB on 22nd July along with a team from BICARA Therapeutics, a Boston-based subsidiary that supports Biocon’s immune-oncology programmes. Nils is a long-standing member of US Cancer Research Institute’s Scientific Advisory Council and currently an advisor for venture capital firm Canaan Partners, Nila Patil is a well-known clinical genomics researcher currently associated with Invitae Corporation.